Cardamonin decreased the protein expression of lipogenic proteins. حسب Peiguang Niu (17044532)

Mean cold pressor threshold overtime (baseline to 12 weeks). حسب Judith I. Tsui (5983160)

الموضوعات:

Mean in cold pressor tolerance overtime (baseline to 12 weeks). حسب Judith I. Tsui (5983160)

الموضوعات:

Association of chemotherapy cycles and nausea and vomiting with the decrease of post-treatment vitamin D concentration (n = 136). حسب Herindita Puspitaningtyas (11618232)

الموضوعات:

The sensitivity analysis results for standardized mean differences of circulating apelin levels between cases with CVDs and controls. حسب Hamed Akbari (8119361)

الموضوعات:

Decreased biofilm formation in the Δ<i>tad123</i> mutant cells. حسب Tra-My Duong-Nu (7300970)

Arm tremor and rigidity during settings (mean ± sd). حسب Verneri Ruonala (12419145)

Mean ± SD of the different parameters relative to bipedal stance on soft support with the eyes open recorded in the Chewing and Hand Grip groups. حسب Cristina Dolciotti (16317330)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات: